The company was acquired by Nanox in a deal announced in (August 2021), with a valuation around $200 million. Its focus on population health and preventative medicine distinguishes it from competitors that are more focused on acute care. The company has 7 FDA-cleared and 10 CE-marked AI solutions for medical imaging.
Cyborg Score Rationale
The company stands 5th in terms of total funding among its competitors. With 7 FDA-cleared and 10 CE-marked AI solutions, Zebra has proven regulatory validation. As part of Nanox, it benefits from a publicly traded parent company and strategic integration with teleradiology assets.
Top Insights
Offers solutions for bone health, fatty liver, respiratory diseases, cardiovascular diseases, and CNS disorders.
Using patient imaging data already available to healthcare systems, algorithms highlight early, previously undetected signs of common chronic diseases, initiating further medical assessment to establish preventative care pathways.
Top competitors include AIdoc, Viz.ai and Qure.ai.
The company has 70 total employees.
Named Competitors
AIdoc — AI-powered medical imaging analytics for clinical decision support
Viz.ai — AI platform for rapid medical imaging diagnosis and stroke alert systems
Qure.ai — Deep learning solutions for automated medical image analysis
TeraRecon — Medical imaging and visualization software solutions
Recent Developments
(June 2026) Zebra Medical Vision received FDA clearance for HealthCCSng, a cardiac-focused imaging tool for analyzing non-gated CT scans and quantifying Coronary Artery Calcium
(April 2026) AIdoc, a competitor, secured $150M in funding
(August 2021) Nanox announced acquisition agreement with valuation around $200 million
Open the full interactive Zebra Medical Vision report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.